Carboplatin-oral etoposide personalised dosing in elderly non-small cell lung cancer patients

European Journal of Cancer

Volumn 34, Issue 11, 1998, Pages 1710-1714

  Frasci, G ^a   Comella, P ^a   Panza, N ^a   De Cataldis, G ^a   Del Gaizo, F ^a   Pozzo, C ^a   Gravina, A ^a   Ruffolo, P ^a   Cioffi, R ^a   Marcatili, P ^a   Della Vittoria, M ^a   Monfardini, S ^a   Comella, G ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Carboplatin; Daily administration; Elderly; Non small cell lung cancer; Oral etoposide; Poor performance status

Indexed keywords

CARBOPLATIN; ETOPOSIDE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; FEVER; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MULTIVARIATE ANALYSIS; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; QUALITY OF LIFE; QUESTIONNAIRES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0032189622     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00207-X     Document Type: Article

References (12)

1. 1. Non-small Cell Lung Cancer Cooperative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patient data from 52 randomised clinical trials. Br Med J 1995, 311, 899-909.
2. 2. Bonomi PD, Finkelstein DM, Ruckdeschel JC, et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 1989, 7, 1602-1613.
3. 3. Waits TM, Johnson DH, Hainsworth JD, et al. Prolonged administration of oral etoposide in non-small cell lung cancer: a phase II trial. J Clin Oncol 1992, 10, 292-296.
4. 4. Evans WK, Radwi A, Tomiak E, et al. Oral etoposide and carboplatin. Effective therapy for elderly patients with small cell lung cancer. Am J Clin Oncol 1995, 18, 149-155.
5. 5. Johnson DH, Hainsworth JD, De Vore R, et al. Carboplatin plus oral etoposide in the management of unresectable non-small cell lung cancer. Preliminary results of a Vanderbilt trial. Oncology 1992, 49(Suppl. 1), 62-67.
6. 6. Castelnau O, Perol M, Vergnenegre A, et al. Carboplatin-VP16 combination in non-small cell lung cancers in the aged patient. A study of the French group in pneumology. Bull Cancer Paris 1985, 82, 63-66.
7. 7. Frasci G, Perillo G, Comella G, et al. Phase I/II study of carboplatin and oral etoposide with granulocyte colony stimulating factor in advanced non-small cell lung cancer. Cancer 1995, 75, 1578-1585.
8. 8. Simon R, Wittes RE, Ellenberg SS. Randomised phase II clinical trials. Cancer Treat Rep 1985, 69, 1375-1381.
9. 9. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981, 47, 207-214.
10. 10. Hollen PJ, Gralla RJ, Kris MG, Potanovich LM. Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale. Eur J Cancer 1993, 29A(Suppl. 1), S51-S58.
11. 11. Gridelli C, Perrone F, Gallo C, et al. Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non small cell lung cancer. A two-stage phase II study. Eur J Cancer 1997, 33, 392-397.
12. 12. Sheperd FA. Single agent gemcitabine activity in non-small cell lung cancer. Lung Cancer 1997, 18(Suppl. 2), 114.